Description
Remogliflozin is a selective inhibitor of sodium-glucose transporter 2 (SGLT2) that promotes blood glucose to be eliminated through the urine. The prodrug Remoglifozin etabonate (GSK 189075) is converted into remogliflozin in vivo, and is suggested for the treatment of type II diabetes.